Now:Home >>About US >>Manegement Team
About UsManagement Team
Quanfu Feng ,Executive VP
MD,Adjunct Professor of Nanjing University of Traditonnal Chinese Medicine ,Tutor of Master. He is an experienced pharma company excective, with over 20 years of marketing and management experience in the industry.
Wenqi Zeng, VPresident of Bioscikin and CMO of Simcere Diagnostics
Dr. Zeng is Chief Medical Officer of Simcere Diagnostics Co. and vice president of Bioscikin. Dr. Zeng was Senior Director of Molecular Genetics at Quest Diagnostics and Laboratory Director of Clinical Genomics at Ambry Genetics. Prior to Ambry, he was co-Director of Clinical Molecular Genetics at City of Hope National Medical Center. Dr. Zeng was fellow of Clinical Molecular Genetics and Human Neurogenetics at Harvard University. He Received his M.D. from Xiang-Ya Medical School, Central South University in China and Ph.D. in Molecular Patholgy/Molecular Genetics from University of Otago. He holds Diploma of American Board of Medical Genetics and Genomics (ABMGG), and is a qualified CAP inspection team leader, and a qualified CAP CLIA lab director in CA, FL and MD. He also has New York state COQ in molecular genetics and molecular oncology.
Max He,Vice President of Medical Informatics
Before joining the BioSciKin Co., Ltd., Dr. Max He was a tenure-track Assistant Professor in the Center for Human Genetics and the Biomedical Informatics Research Center at Marshfield Clinic. Meanwhile, he was an adjunct Professor in the Computation and Informatics in Biology and Medicine at University of Wisconsin-Madison. Prior to assuming his positions at Marshfield, Dr. He served as Assistant Professor of Medical Genetics in the Center for Human Genome Variation at Duke University Medical School. The focus of his research is on developing statistical approaches and computational tools on Big Data infrastructures for genomic medicine. Several Big Data based toolsets developed by him and his team have shown practical applications in which genetic diagnosis can potentially be applied in clinical diagnosis and/or personalized treatment by discovery of clinically actionable genetic variants.
Ruikun Zhang, Excecutive BD Director
MBA(Business School Maastricht), nearly 20 years drug R&D experience (Apotex, XBL-China)
Mingxi Li,Board Secretary
PhD.(Univ.of Illinois at Urbana-Champaign) 5+ years biopharma investment experience
Yong Zhao, Director of Preclinical Study
PhD. ,(Cornell Univ.) Post-doctorate in Harvard Medical School Over 7 years bioscience experience(Simcere, Shanghai Hengrui)
Hong Qi, Quality Science Director
Ph.,D,(Nanjing Univ.) 17 years experience of life-science R&D (Newcastle University, Oxford University, Merck, Simcere etc. )
南京百家汇创业社区 版权所有